Results
1
Companies which are more than 50% undervalued based on analyst price target.
1 companies
Lytix Biopharma
Market Cap: NOK 621.4m
A clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.
LYTIX
NOK 8.04
7D
-4.3%
1Y
-13.0%